Please assess the completion status of the following clinical trial:

Trial Title: MEsenchymal StEm Cells for Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 50 years~* Disease duration 2 to 10 years (included)~* Diagnosis of MS~Relapsing remitting MS (RRMS) not responding to at least a year of attempted therapy with one or more of the approved therapies (beta-interferon, glatiramer acetate, natalizumab, mitoxantrone, fingolimod) as evidenced by one or more of the following:~* more or egal 1 clinically documented relapse in past 12 months~* more or egal 2 clinically documented relapses in last 24 months~* more or egal 1 GEL at MRI performed within the last 12 months~Secondary progressive MS (SPMS) not responding to at least a year of attempted therapy with one or more of the approved therapies (beta-interferon, glatiramer acetate, natalizumab, mitoxantrone, fingolimod) as evidenced by both::~* With more or egal 1 clinically documented relapse in the last twelve months~* Without on-going relapses, but with more or egal 1 GEL at MRI performed within the last 12 months.~Primary progressive MS (PPMS) patients with all the following features:~* an increase ofmore or egal 1 EDSS point (if at inclusion EDSS inferior or egal 5.0) or 0.5 EDSS point (if at inclusion EDSS more or egal 5.5), in the last twelve months~* more or egal 1 GEL at MRI performed within the last 12 months~* Positive cerebrospinal fluid (CSF) (oligoclonal banding).~  * EDSS (Expanded Disability Status Scale) 3.0 to 6.5~ * Women of childbearing age with an effective contraception.~Exclusion Criteria:~* RRMS not fulfilling inclusion criteria~* SPMS not fulfilling inclusion criteria~* PPMS not fulfilling inclusion criteria~* Inferior to 3 months since treatment with any immunosuppressive therapy including natalizumab and fingolimod~* Inferior or egal to 1 month since last treatment with interferon-beta or glatiramer acetate~* Corticosteroid treatment Inferior or egal to 30 days~* Relapse inferior or egal to 60 days~* Any active or chronic infection including infection with HIV1-2 (Human Immunodeficiency Virus 2) or HTLV I-II (Human T-lymphotropic virus I-II) or Syphilis or chronic Hepatitis B or Hepatitis C inferior to 1 month~* Previous history of a malignancy other than basal cell carcinoma of the skin or carcinoma in situ that has been in remission for more than one year~* Severely limited life expectancy by another co-morbid illness~* History of previous diagnosis of myelodysplasia or previous hematologic disease or current clinically relevant abnormalities of white blood cell counts~* Pregnancy or risk or pregnancy (this includes patients that are unwilling to practice active contraception during the duration of the study)\*\*~* eGFR (estimated Glomerular Filtration Rate ) inferior to 60 mL/min/1.73m2 or known renal failure or inability to undergo MRI examination.~* Inability to give written informed consent in accordance with research ethics board guidelines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Mesenchymal stem cells (Type: EXPERIMENTAL): At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
- Suspension media (Type: PLACEBO_COMPARATOR): At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0

Based on this trial design, predict the completion outcome and termination type (if applicable).